Financial StabilityLRMR ended 2024 with $183.5M in cash, cash equivalents, and marketable securities, which provides runway into 2Q26.
Regulatory ProgressThe company made significant regulatory progress this past quarter with nomlabofusp (nomla) for Friedreich’s Ataxia, laying down a path toward accelerated approval.
Therapeutic PotentialNomlabofusp has the potential to be the first therapy to address frataxin deficiency, which is the root cause of disease in Friedreich's ataxia.